Valamehr Bahram, President and CEO of Fate Therapeutics ($FATE), made two open market sales of company shares over the past year, totaling about $21,000. His most recent sale occurred on January 9, 2026. These sales rank 11,012th among 11,678 insiders in our database, well below the average of $8.6 million per seller and 6.4 transactions. He made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 15, 2026 | FATE THERAPEUTICS INC | $FATE | Valamehr Bahram | President and CEO | A | Stock Option (Right to Buy) | 1300000 | $0.00 | 1,300,000.0000 | 118,998,693 | 9999.99% | 1.09% |
| Jan. 15, 2026 | FATE THERAPEUTICS INC | $FATE | Valamehr Bahram | President and CEO | A | Common Stock | 335000 | $0.00 | 664,708.0000 | 118,998,693 | 101.61% | 0.28% |
| Jan. 9, 2026 | FATE THERAPEUTICS INC | $FATE | Valamehr Bahram | President and CEO | S | Common Stock | 5190 | $1.07 | 329,708.0000 | 118,998,693 | 1.55% | 0.00% |
| Aug. 4, 2025 | FATE THERAPEUTICS INC | $FATE | Valamehr Bahram | President and CEO | S | Common Stock | 14466 | $1.06 | 334,898.0000 | 113,685,177 | 4.14% | 0.01% |
| Jan. 16, 2025 | FATE THERAPEUTICS INC | $FATE | Valamehr Bahram | President and CEO | A | Stock Option (Right to Buy) | 1300000 | $0.00 | 1,300,000.0000 | 113,685,177 | 9999.99% | 1.14% |
| Jan. 10, 2025 | FATE THERAPEUTICS INC | $FATE | Valamehr Bahram | President and CEO | S | Common Stock | 8705 | $1.54 | 349,364.0000 | 113,685,177 | 2.43% | 0.01% |
| July 29, 2024 | FATE THERAPEUTICS INC | $FATE | Valamehr Bahram | Chief R&D Officer | A | Common Stock | 200000 | $0.00 | 358,069.0000 | 98,411,162 | 126.53% | 0.20% |
| Feb. 1, 2024 | FATE THERAPEUTICS INC | $FATE | Valamehr Bahram | Chief R&D Officer | A | Stock Option (Right to Buy) | 450000 | $0.00 | 450,000.0000 | 98,411,162 | 9999.99% | 0.46% |
| Jan. 9, 2024 | FATE THERAPEUTICS INC | $FATE | Valamehr Bahram | Chief R&D Officer | S | Common Stock | 11271 | $4.38 | 158,069.0000 | 98,411,162 | 6.66% | 0.01% |
| Feb. 6, 2023 | FATE THERAPEUTICS INC | $FATE | Valamehr Bahram | Chief R&D Officer | A | Stock Option (Right to Buy) | 450000 | $0.00 | 450,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 12, 2023 | FATE THERAPEUTICS INC | $FATE | Valamehr Bahram | Chief R&D Officer | M | Stock Option (Right to Buy) | 423 | $0.00 | 0.0000 | 0 | 0.00% | 0.00% |
| Jan. 12, 2023 | FATE THERAPEUTICS INC | $FATE | Valamehr Bahram | Chief R&D Officer | M | Common Stock | 423 | $1.37 | 169,340.0000 | 0 | 0.25% | 0.00% |
| Jan. 10, 2023 | FATE THERAPEUTICS INC | $FATE | Valamehr Bahram | Chief R&D Officer | S | Common Stock | 10917 | $5.24 | 168,917.0000 | 0 | 6.07% | 0.00% |